glp 1 and sarcopenia Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? Novel Insights into the Roles
Description
They may face new restrictions
Ask your pharmacist
Weight change and risk of venous thromboembolism: the Troms study
Work in the Trapp laboratory is supported by the Medical Research Council (MRC) (MR/N02589X/1), the National Institutes of Health (NIH) and the European Foundation for the Study of Diabetes (EFSD)
The medication works by reducing appetite and increasing satiety, which leads to a lower calorie intake and an initial rapid weight loss
